Quick Links: Skip to main page content
Skip to Search
Skip to Topics Menu
Skip to Common Links
U.S. Food & Drug Administration
Follow FDA
En Español
Search FDA
Home
Food
Drugs
Medical Devices
Radiation-Emitting Products
Vaccines, Blood & Biologics
Animal & Veterinary
Cosmetics
Tobacco Products
Pediatric Studies Characteristics - Detail
FDA Home
Pediatrics
Pediatric Studies Characteristics
Detail
-
Please note:
JavaScript must be enabled for this application to work properly.
Check your settings
if you are unsure if your JavaScript is enabled.
Approval Date:
04/06/2011
Trade Name:
Invega
Generic or Proper Name (*):
paliperidone
Indications Studied:
Treatment of schizophrenia
Therapeutic Category:
Antipsychotic
Ages Studied:
10-17 years
Study #:
2
Study Type:
Efficacy/Safety/Tolerability
Study Design:
Blind/Placebo
No Patients:
201
No Centers:
35
No Countries:
5
BPCA(B), PREA(P):
B, P
Asian:
47
Black:
17
White:
136
Hispanic/Latino:
4
Non-Hispanic/Non Latino:
196
-
-